Investment Column: Chemring defensive in dangerous times

Alkane Energy; Alliance Pharma


Our view: Buy

Share price: 2160p (+170p)

We don't always get it right, but those of you who followed our advice towards the end of last year, when we first suggested buying Chemring shares at 1613p, can certainly afford a cheer.

The stars still seem aligned for the defence group, which makes consumable counter-measures and "energetics", such as flares. The public sector is its biggest client in a host of different countries, and it makes 60 per cent of its revenues in dollars and euros.

According to Chemring's brokers at Investec, turnover will reach £470m this year, up from £350m in 2008. The group's orders are up 39 per cent.

Yes, the stock has appreciated at a terrific rate in the past few months but, according to analysts at RBS, it is still worth buying. "The shares are currently trading on a October 2009 price earnings ratio of 10.1 times, and enterprise value to Ebitda of 6.7 times," they say. "This is still a significant discount to [a] number of larger, but in our view, lower quality peers in the FTSE 350 aerospace and defence sector[s]."

The shares are about as defensive as you get in these markets and, while we would not advise sitting on the stock indefinitely, if investors think the downturn will last for the foreseeable future, Chemring shares are worth keeping hold of.

Barring anything unexpected, and there was no sign of anything untoward yesterday's trading update, the shares will have a bumper 2009. Buy.

Alkane Energy

Our view: Buy

Share price: 16.5p (+1.75p)

You have to take your hat off to Alkane Energy. For good reason, and despite the misery for some companies in the continuing recession, it is upbeat about the future and says it is having no trouble in attracting investors, at least to meetings.

The Aim-listed company specialises in building and operating methane extraction plants, largely at disused mines in the Midlands. Alkane says the energy is clean and, with stellar full-year numbers announced yesterday, no debts and the price of its energy fixed for another year, the group is confident that its investors will benefit from holding the stock.

Neil O'Brien, Alkane's new chief executive, says he is excited about the future and that for the first time since the collapse of Lehman Brothers, he has filled up his diary for the next few days with meetings in the City – a sure sign that confidence is returning, albeit gradually. Whether this is the case is in our view questionable, but that does not detract from the fact that investors are prepared to listen to solid small caps with a good story. Alkane will start more projects this year, and the resultant power will not be locked in at current market levels, allowing the group to take advantage of higher energy prices in the coming year, Mr O'Brien says. A new site costs an average of £2.5m, and Alkane says it has enough cash in the bank to cover at least three projects this year.

There are clearly compelling reasons to buy Alkane shares. The big white elephant in the room, lest investors forget it, is that as a small-cap company, Alkane will suffer disproportionately with any slight change in sentiment. The shares rose 11.7 per cent yesterday and experts at house broker Brewin Dolphin predictably say the stock is a buy with a 24p price target. We would tentatively agree that they will rise. Buy.

Alliance Pharma

Our view: Hold

Share price: 8.25p (+1.1p)

To a casual observer, Alliance Pharma may not look too different to how it did two years ago. The chief executive, John Dawson, would disagree, saying that the group's marketing strategy has changed and, with a new venture capital investor, MVM, on board, the need for cash from outside to fund all-important acquisitions, has gone. The difference, Mr Dawson would argue, is reflected in its share price – up 75 per cent since December.

The group specialises in buying established, off-patent drugs that do not make enough money to attract generics firms. Yesterday, it published its full-year results, saying its pre-tax profits were £2.4m – up from a loss of £3.2m last year. Most significantly for investors, the group said it expects to start paying a dividend within the next 12 months. Despite the shares trading 15.8 per cent higher, analysts at house broker Numis reckon the stock is still undervalued. They said the shares were worth 11p, based on an average of sector peers' enterprise value to Ebitda.

While acknowledging that the shares have performed well in recent months, we see few catalysts from here. We would wait for some softening in the share price before buying. Hold.

Suggested Topics
PROMOTED VIDEO
Life and Style
fashion

News
The Magna Carta
archaeologyContemporary account of historic signing discovered
News
Jeremy Paxman has admitted he is a 'one-nation Tory' and complained that Newsnight is made by idealistic '13-year-olds' who foolishly think they can 'change the world'.
peopleFormer Newsnight presenter is being touted for a brand new role
News
The two-year-old said she cut off her fringe because it was getting in her eyes
news

Video: It is the type of thing no parent wants to hear

Arts and Entertainment
Avatar grossed $2.8bn at the box office after its release in 2009
film
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Financial Sales Executives

£19000 - £24000 per annum: Recruitment Genius: Due to our clients continuing s...

Argyll Scott International: Service Desk Analyst

£20000 - £22000 per annum: Argyll Scott International: Service Desk Analyst Re...

Argyll Scott International: 2x Service Desk Analyst

£20000 - £22000 per annum: Argyll Scott International: Service Desk Analyst Re...

Recruitment Genius: Senior Execution Trader

£30000 - £250000 per annum: Recruitment Genius: A global Rolling Spot FX, Comm...

Day In a Page

Homeless Veterans Christmas Appeal: ‘We give them hope. They come to us when no one else can help’

Christmas Appeal

Meet the charity giving homeless veterans hope – and who they turn to when no one else can help
Should doctors and patients learn to plan humane, happier endings rather than trying to prolong life?

Is it always right to try to prolong life?

Most of us would prefer to die in our own beds, with our families beside us. But, as a GP, Margaret McCartney sees too many end their days in a medicalised battle
Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night - is that what it takes for women to get to the top?

What does it take for women to get to the top?

Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night and told women they had to do more if they wanted to get on
Christmas jumper craze: Inside the UK factory behind this year's multicultural must-have

Knitting pretty: British Christmas Jumpers

Simmy Richman visits Jack Masters, the company behind this year's multicultural must-have
French chefs have launched a campaign to end violence in kitchens - should British restaurants follow suit?

French chefs campaign against bullying

A group of top chefs signed a manifesto against violence in kitchens following the sacking of a chef at a Paris restaurant for scalding his kitchen assistant with a white-hot spoon
Radio 4 to broadcast 10-hour War and Peace on New Year's Day as Controller warns of cuts

Just what you need on a New Year hangover...

Radio 4 to broadcast 10-hour adaptation of War and Peace on first day of 2015
Cuba set to stage its first US musical in 50 years

Cuba to stage first US musical in 50 years

Claire Allfree finds out if the new production of Rent will hit the right note in Havana
Christmas 2014: 10 best educational toys

Learn and play: 10 best educational toys

Of course you want them to have fun, but even better if they can learn at the same time
Paul Scholes column: I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season

Paul Scholes column

I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season
Lewis Moody column: Stuart Lancaster has made all the right calls – now England must deliver

Lewis Moody: Lancaster has made all the right calls – now England must deliver

So what must the red-rose do differently? They have to take the points on offer 
Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

It's in all our interests to look after servicemen and women who fall on hard times, say party leaders
Millionaire Sol Campbell wades into wealthy backlash against Labour's mansion tax

Sol Campbell cries foul at Labour's mansion tax

The former England defender joins Myleene Klass, Griff Rhys Jones and Melvyn Bragg in criticising proposals
Nicolas Sarkozy returns: The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?

Sarkozy returns

The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?
Is the criticism of Ed Miliband a coded form of anti-Semitism?

Is the criticism of Miliband anti-Semitic?

Attacks on the Labour leader have coalesced around a sense that he is different, weird, a man apart. But is the criticism more sinister?
Ouija boards are the must-have gift this Christmas, fuelled by a schlock horror film

Ouija boards are the must-have festive gift

Simon Usborne explores the appeal - and mysteries - of a century-old parlour game